TransMedics Group Quarterly Cash Flow Statement
NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TransMedics Group free cash flow
In the quarter ended Jun 30, 2026, TransMedics Group generated $17.3 million of operating cash flow and spent $7.1 million on capital expenditures. That left free cash flow of $10.2 million, a free-cash-flow margin of 5.4% of revenue. Free cash flow was down 87.6% from the prior year's $82.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
TransMedics Group cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 14.68M | 7.32M | 105.38M | 24.32M | 34.91M | 25.68M | 6.86M | 4.22M | 12.19M | 12.20M | 4.03M | -25.42M |
| Net Income growth (YoY) | -57.94% | -71.52% | +1436.87% | +476.83% | +186.26% | +110.56% | +70.11% | — | — | — | — | — |
| Depreciation & Amortization | 10.24M | 11.86M | 7.47M | 6.85M | 6.73M | 6.14M | 5.68M | 5.18M | 4.60M | 4.30M | 3.60M | 1.89M |
| Stock-Based Compensation | 8.61M | 9.95M | 9.39M | 9.14M | 9.37M | 8.96M | 10.77M | 7.94M | 7.64M | 6.87M | 5.72M | 5.19M |
| Change in Working Capital | -22.34M | -7.29M | -11.52M | 15.54M | 38.67M | -39.09M | -7.47M | -15.53M | 2.00K | -27.53M | -10.08M | -21.00M |
| Operating Cash Flow | 17.31M | 24.53M | 34.51M | 69.57M | 91.61M | -2.85M | 19.66M | 6.86M | 25.72M | -3.44M | 8.30M | -6.87M |
| Capital Expenditures | -7.09M | -36.66M | -15.51M | -7.62M | -9.07M | -27.04M | -13.61M | -48.20M | -23.76M | -44.17M | -41.82M | -107.72M |
| Investing Cash Flow | -7.09M | -36.66M | -15.51M | -7.62M | -9.07M | -27.04M | -13.61M | -47.76M | -23.76M | -44.17M | -41.82M | -149.83M |
| Financing Cash Flow | 970.00K | 3.76M | 3.10M | 3.64M | 7.09M | 3.03M | 1.19M | 7.86M | 10.64M | 3.19M | 924.00K | 1.52M |
| Net Change in Cash | 10.94M | -8.69M | 22.19M | 65.60M | 90.43M | -26.51M | 6.56M | -32.66M | 12.53M | -44.59M | -32.30M | -155.35M |
| Free Cash Flow | 10.22M | -12.12M | 19.00M | 61.95M | 82.53M | -29.89M | 6.06M | -41.35M | 1.96M | -47.61M | -33.51M | -114.59M |
This table shows 12 quarterly periods of TransMedics Group's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TMDX's reporting calendar. What is a cash flow statement?